Cipla’s US Arm Recalls Over 400 Cartons of Generic Anti Cancer Drug Nilotinib: USFDA
Manufacturing Issue Triggers Recall of Nilotinib Capsules in Two Strengths
New Delhi, March 8: Cipla’s US-based subsidiary has recalled more than 400 cartons of a generic anti cancer medication from the United...
anti-cancer medicine
cancer treatment
cipla
generic medicine
generics market
india
manufacturing issue
nilotinib
pharmaceutical industry
pharmaceutical manufacturing
pharmaceutical recall
sun pharmaceutical industries
united states
us food and drug administration (usfda)
warren, new jersey
